Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16753139 | 0.89 | MAPK14 (0.50) | MAPK14MCHR1KCNH2LTA4HKMT2A | |
| SCHEMBL18500627 | 0.86 | MAPK14 (0.52) | MAPK14MCHR1KCNH2LTA4HKMT2A | |
| SCHEMBL17504023 | 0.85 | MAPK14 (0.46) | MAPK14MCHR1KCNH2LTA4HKMT2A | |
| SCHEMBL4468416 | 0.81 | MAPK14 (0.54) | MAPK14MCHR1KCNH2KMT2ASMN1; SMN2 | |
| SCHEMBL19470113 | 0.80 | MAPK14 (0.56) | MAPK14MCHR1KCNH2KMT2ASMN1; SMN2 | |
| SCHEMBL19470112 | 0.80 | MAPK14 (0.56) | MAPK14MCHR1KCNH2KMT2ASMN1; SMN2 | |
| SCHEMBL936400 | 0.80 | GCK (0.40) | ADAM17 | |
| SCHEMBL17456364 | 0.79 | MAPK14 (0.61) | MAPK14MCHR1KCNH2 | |
| SCHEMBL16753163 | 0.77 | MAPK14 (0.47) | MAPK14MCHR1KCNH2LTA4HKMT2A | |
| SCHEMBL16753140 | 0.75 | MAPK14 (0.50) | MAPK14MCHR1KCNH2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| WO-2011009845-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | MAPK14 726/4885MCHR1 4738/4885KCNH2 1635/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | MAPK14 726/4885MCHR1 4738/4885KCNH2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.